OvMark: A user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Madden, Stephen F ^a   Clarke, Colin ^a   Stordal, Britta ^c   Carey, Mark S ^f   Broaddus, Russell ^e   Gallagher, William M ^b   Crown, John ^a   Mills, Gordon B ^e   Hennessy, Bryan T ^d  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d BEAUMONT HOSPITAL   (Ireland)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PLATINUM COMPLEX; STROMAL CELL DERIVED FACTOR 1; TAXANE DERIVATIVE; TUMOR MARKER; MESSENGER RNA; TRANSCRIPTOME;

ACCESS TO INFORMATION; ARTICLE; BIOINFORMATICS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; COMPUTER PROGRAM; COMPUTER SYSTEM; CORRELATION ANALYSIS; CXCL12 GENE; DISEASE FREE SURVIVAL; DNAH12; GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; INTERNET; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; SNAI3 GENE; VWA3A GENE; ALGORITHM; COMPUTER INTERFACE; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; METABOLISM; OVARY TUMOR; PROGNOSIS; TUMOR GENE;

ALGORITHMS; BIOMARKERS, TUMOR; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROGNOSIS; RNA, MESSENGER; TRANSCRIPTOME; USER-COMPUTER INTERFACE;

EID: 84934928206     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-241     Document Type: Article

References (57)

1. Hennessy BT, Coleman RL, Markman M: Ovarian cancer. Lancet 2009,374(9698):1371-1382. 10.1016/S0140-6736(09)61338-6
2. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Galaal K: Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013, 2:CD008765.
3. Le Page C, Huntsman DG, Provencher DM, Mes-Masson A-M: Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers 2010,2(2):913-954. 10.3390/cancers2020913
4. Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB: Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010,28(22):3570-3576. 10.1200/JCO.2009.27.2997
5. Madden SF, Clarke C, Gaule P, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM: BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 2013,15(4):R52. 10.1186/bcr3444
6. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M: Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 2013,34(10):2300-2308. 10.1093/carcin/bgt208
7. Iorio MV, Visone R, Leva GD, Donati V, Petrocca F, Casalini P, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M: MicroRNA signatures in human ovarian cancer. Cancer Res 2007,67(18):8699-8707. 10.1158/0008-5472.CAN-07-1936
8. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009,136(2):215-233. 10.1016/j.cell.2009.01.002
9. Baskerville S, Bartel DP: Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005,11(3):241-247. 10.1261/rna.7240905
10. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res 2004,14(10A):1902-1910. 10.1101/gr.2722704
11. Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007,8(1):166. 10.1186/1471-2164-8-166
12. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD, Australian Ovarian Cancer Study Group: Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011,6(4):e18064. 10.1371/journal.pone.0018064
13. Delfino KR, Rodriguez-Zas SL: Transcription factor-MicroRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One 2013,8(3):e58608. 10.1371/journal.pone.0058608
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003,4(2):249-264. 10.1093/biostatistics/4.2.249
15. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucl Acids Res 2002,30(4):e15-e15. 10.1093/nar/30.4.e15
16. Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2005,33(Database issue):D54-D58.
17. Guberman JM, Ai J, Arnaiz O, Baran J, Blake A, Baldock R, Chelala C, Croft D, Cros A, Cutts RJ, Di Génova A, Forbes S, Fujisawa T, Gadaleta E, Goodstein DM, Gundem G, Haggarty B, Haider S, Hall M, Harris T, Haw R, Hu S, Hubbard S, Hsu J, Iyer V, Jones P, Katayama T, Kinsella R, Kong L, Lawson D, et al.: BioMart central portal: an open database network for the biological community. Database (Oxford) 2011, 2011:bar041.
18. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008,68(13):5478-5486. 10.1158/0008-5472.CAN-07-6595
19. Crijns APG, Fehrmann RSN, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG: Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009,6(2):e1000024.
20. Denkert C, Budczies J, Darb-Esfahani S, Györffy B, Sehouli J, Könsgen D, Zeillinger R, Weichert W, Noske A, Buckendahl AC, Müller BM, Dietel M, Lage H: A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol 2009,218(2):273-280. 10.1002/path.2547
21. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One 2012,7(2):e30550. 10.1371/journal.pone.0030550
22. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D: Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One 2011,6(3):e18202. 10.1371/journal.pone.0018202
23. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010,28(22):3555-3561. 10.1200/JCO.2009.27.5719
24. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X, Mechta-Grigoriou F: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011,17(12):1627-1635. 10.1038/nm.2512
25. Home - The Cancer Genome Atlas - Cancer Genome - TCGA [Internet]. 2014. Available from: http://cancergenome.nih.gov/
26. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008,455(7216):1061-1068. 10.1038/nature07385
27. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong K, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ: A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009,16(6):521-532. 10.1016/j.ccr.2009.10.018
28. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005,23(31):7911-7918. 10.1200/JCO.2005.02.9363
29. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD, Australian Ovarian Cancer Study Group: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008,14(16):5198-5208. 10.1158/1078-0432.CCR-08-0196
30. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K: Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets. PLoS One 2010,5(3):e9615. 10.1371/journal.pone.0009615
31. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K, et al.: High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012,18(5):1374-1385. 10.1158/1078-0432.CCR-11-2725
32. Rainer J, Ploner C, Jesacher S, Ploner A, Eduardoff M, Mansha M, Wasim M, Panzer-Grümayer R, Trajanoski Z, Niederegger H, Kofler R: Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia 2009,23(4):746-752. 10.1038/leu.2008.370
33. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, Al-Kuraya KS: Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009,8(1):74. 10.1186/1476-4598-8-74
34. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008,3(7):e2633. 10.1371/journal.pone.0002633
35. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB: Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010,16(11):2999-3010. 10.1158/1078-0432.CCR-09-3233
36. Krockenberger M, Kranke P, Häusler S, Engel JB, Horn E, Nürnberger K, Wischhusen J, Dietl J, Hönig A: Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res 2012,32(12):5233-5238.
37. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K: Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 2011,4(9):1401-1408. 10.1158/1940-6207.CAPR-10-0402
38. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL: Expression of the Cell Cycle Inhibitor p27KIP1 Is a New Prognostic Marker Associated with Survival in Epithelial Ovarian Tumors. Am J Pathol 1999,154(1):119-125. 10.1016/S0002-9440(10)65258-3
39. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB: Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000,6(4):1415-1421.
40. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R: Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010,107(46):19997-20002. 10.1073/pnas.1009010107
41. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012,12(1):91. 10.1186/1471-2407-12-91
42. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM: The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer 2012,106(7):1306-1313. 10.1038/bjc.2012.49
43. Chen YL, Cheng WF, Chang MC, Lin HW, Huang CT, Chien CL, Chen CA: Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol 2013,131(1):63-68. 10.1016/j.ygyno.2013.07.105
44. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995,57(1):289-300.
45. Schröder MS, Culhane AC, Quackenbush J, Haibe-Kains B: survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 2011,27(22):3206-3208. 10.1093/bioinformatics/btr511
46. Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G: Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 2014,106(5):dju049. 10.1093/jnci/dju049
47. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ: Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. JNCI J Natl Cancer Inst 2014,106(5):dju048. 10.1093/jnci/dju048
48. Boyerinas B, Park S-M, Hau A, Murmann AE, Peter ME: The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010,17(1):F19-F36. 10.1677/ERC-09-0184
49. Bose CK: Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol Res 2008,17(5):231-238. 10.3727/096504008786111383
50. Chen X, Jiang W, Wang Q, Huang T, Wang P, Li Y: Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network. BMC Med Genomics 2012,5(1):43. 10.1186/1755-8794-5-43
51. Katoh M, Katoh M: Identification and characterization of human SNAIL3 (SNAI3) gene in silico. Int J Mol Med 2003,11(3):383-388.
52. Mertens-Walker I, Baxter RC, Marsh DJ: Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett 2012,324(2):152-159. 10.1016/j.canlet.2012.05.017
53. Shin N, You KT, Lee H, Kim WK, Song M, Choi HJ, Rhee H, Nam SW, Kim H: Identification of frequently mutated genes with relevance to nonsense mediated mRNA decay in the high microsatellite instability cancers. Int J Cancer 2011,128(12):2872-2880. 10.1002/ijc.25641
54. Gyorffy B, Lánczky A, Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012,19(2):197-208. 10.1530/ERC-11-0329
55. Katoh Y, Katoh M: Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 2008,22(3):271-275.
56. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, Gibbs RA, Sander C, Hayes DN, Gunaratne PH, Network Cancer Genome Atlas Research: Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 2012,7(3):e34546. 10.1371/journal.pone.0034546
57. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, et al.: Toward the blood-borne miRNome of human diseases. Nat Methods 2011,8(10):841-843. 10.1038/nmeth.1682